Paper

Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias.

Published Jan 15, 1992 · DOI · W. Wong, W. Wong, Harris N. Paviou

The American journal of cardiology

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Study Snapshot

Sematilide prolongs QTc in patients with chronic high-frequency ventricular arrhythmias, but does not alter PR or QRS, and slowed heart rate at high concentrations.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias.

References

Citations